key: cord-0965614-j1rhuyl8
authors: Grandjean Lapierre, S.; Bedwani, S.; Deblois, F.; Fortin, A.; Zamorano Cuervo, N.; Zerouali, K.; Caron, E.; Morency Potvin, P.; Gagnon, S.; Nguissan, N.; Arlotto, P.; Hardy, I.; Boutin, C.-A.; Tremblay, C.; Coutlee, F.; de Guise, J.; Grandvaux, N.
title: Clinical Evaluation of In House Produced 3D Printed Nasopharyngeal Swabs for COVID-19 Testing
date: 2021-05-30
journal: nan
DOI: 10.1101/2021.05.26.21257548
sha: 9ecb067075cd4a0a74e5184131262d0be9404319
doc_id: 965614
cord_uid: j1rhuyl8

3D printed alternatives to standard flocked swabs were rapidly developed to provide a response to the unprecedented and sudden need for an exponentially growing amounts of diagnostic tools to fight the pandemics of COVID-19. In light of the anticipated shortage, an hospital-based 3D printing platform was implemented in our institution for the production of swabs for nasopharyngeal and oropharyngeal sampling based on the freely available open-sourced design made available to the community by University of South Florida's Health Radiology and Northwell Health System teams as replacement for locally used commercial swabs. Validation of our 3D printed swabs was performed by a head-to-head diagnostic accuracy study of the 3D printed Northwell model with the cobas PCR Media swabs sample kit. We observed an excellent concordance (total agreement 96.8%, Kappa 0.936) in results obtained with the 3D printed and flocked swabs indicating that the in-house 3D printed swab can be used reliably in a context of shortage of flocked swabs. To our knowledge, this is the first study to report on autonomous hospital-based production and clinical validation of 3D printed swabs.

In December 2019, the outbreak of an atypical severe respiratory syndrome, now known as 37 coronavirus 19 disease in Wuhan, China (1), rapidly led to the identification of the 38

Severe acute respiratory syndrome (SARS)-Coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is highly 39 a complete set of mechanical tests (11). In our hospital-based production, we used the model 79 referred to as "Northwell model" to which a breaking point located at 80 mm from the tip was 80 added to the original design. Medical, #RS120). Appropriate sealing was verified visually. Sterilization was performed by 97 autoclaving using a pre-vacuum steam cycle set at 132°C (270°F) for 4 min followed by a 30 min 98 drying period. 99 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) To verify the efficacy of the sterilization procedure for each lot, the head of two swabs per 100 production lot were inoculated with 10 μL of the Biological Indicator Geobacillus 101 stearothermophilus spore suspension (1.7*10 7 CFU/0.1 mL; Steris Corporation, #NA-091) under 102 sterile conditions (12). Inoculated swabs were held horizontally for 30min and further let dry 103 vertically for 24 h under sterile conditions. Next, dried swabs were sealed individually in 104 sterilization pouches. One of the inoculated swabs was subjected to sterilization as described 105

above, together with all swabs from the same lot. The other inoculated swab was kept in the pouch 106

and was not sterilized. The two inoculated swabs were broken at the breakpoint and inserted into 107 a bacteriology tube (Sarstedt, #62515006) containing 5 mL of tryptic soy broth culture media 108 (Sigma Aldrich, #1463170010). Bacteria growth was monitored by incubation at 55°C with orbital 109 agitation for 7 days. A culture media only negative control was also used. OD600nm was measured 110 on day 7 to assess bacterial growth. 111 112

Swabs showing excessive warping post-sterilization were discarded after visual inspection. Basic 114 mechanical testing was performed using a guide formed by 3 semicircular canals with a minimum 115 radius of 15, 25 and 35 mm, respectively, that allowed testing the flexibility of swabs. The test 116 was successful if the head and neck remained intact after going through each canal. The final test 117 consisted in breaking the swab in half with one hand at its breaking point. 118 119 120 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

This study was performed in our institution's COVID-19 rapid screening clinic and included 122 symptomatic healthcare workers self-presenting for COVID-19 diagnostic testing. During an 123 initial recruitment phase, participants were tested simultaneously with both the cobas PCR Media® 124 swab sample kit (Roche Diagnostics, Laval, Quebec, Canada) and the 3D printed swabs. As for 125

any COVID-19 test, all results were transmitted to the institution occupational health and safety 126 office and public health authorities. In a subsequent recruitment phase, to increase the number of 127 positive samples within the study, patients having previously tested positive on routine testing 128 were contacted by clinical research personnel and offered to participate in the study. For those 129 participants, both sampling techniques were repeated simultaneously. 130 131

A sequential oropharyngeal and nasopharyngeal sampling with each single swab was performed. 133

For the nasopharyngeal sampling, Cobas PCR Media swabs sample kit and 3D printed swab were 134 used in the same nostril in a randomized order. The swabs were transferred separately to tubes 135 containing the cobas PCR Media transport medium before proceeding with the PCR analysis. All 136 samples were tested on the FDA emergency use authorization (EUA) approved and locally 137 validated cobas 8800 automated RT-PCR system which simultaneously tests the ORF1 a/b and E-138 gene viral molecular targets together with an internal control (13). 139

In conclusion, our study adds to the few clinical validation studies that demonstrated safety and 140 accuracy of 3D swabs. Our study is unique in that it tested a fully integrated hospital-based 141 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 30, 2021. ; https://doi.org/10.1101/2021.05.26.21257548 doi: medRxiv preprint production of 3D-printed swabs as initially suggested by the USF and Northwell Health system 142 groups. Our clinical trial has demonstrated that our local 3D printed swab production line offers a 143 reliable local alternative to commercial swabs and therefore confirms that it is a viable local 144 response to provide replacements in the event of pandemic supply chain disruption. 145

The Lilliefors statistical test adapted from the Kolmogorov-Smirnov nonparametric test was used 147 to assess data distribution normality. The Wilcoxon matched-pairs test for non-normal 148 distributions was used to evaluate the difference between means of RT-PCR cycle thresholds (Ct) 149 obtained following both sampling methods. Concordance analysis between both assays using 

A total of 63 participants were enrolled in the study. Thirty-two participants tested negative and 184 31 tested positive with the cobas 8800 SARS-CoV-2 PCR. Swabs from the 3 distinct printed lots 185 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 30, 2021. ; https://doi.org/10.1101/2021.05.26.21257548 doi: medRxiv preprint were used for sample collection (batch 1, n = 21, 11 positives, 10 negatives; batch 2, n = 21, 11 186 positives; 10 negatives; batch 3, n = 21, 9 positives, 12 negatives). Lilliefors statistical test and 187

Kolmogorov-Smirnov nonparametric test showed that cycle threshold (Ct) distributions for both 188 swabs were not standard (p=0.12). PCR results for the E-gene (p=0.27), ORF1 gene (p=0.92) and 189 internal control (p=0.59) did not show significant Ct differences between flocked swabs and 3D 190 printed swabs (Figure 3 and In this report, we described the implementation of a hospital-based 3D printing platform for the 203 production of swabs for nasopharyngeal and oropharyngeal sampling for COVID-19 diagnosis. of the assay (13, 15). Given the complexity and discomfort associated with repeated simultaneous 222 nasopharyngeal testing and the necessity to validate the use of 3D printed swab in a controlled 223 head-to-head approach, we did not include other transport media in our validation study. We did 224 not observe significant Ct values differences between swabs for the ORF1 and E SARS-CoV-2 225 genes in the Roche cobas assay. These observations are in agreement with the data from the clinical 226 trial performed by the USF and Northwell system teams using the 3D printed "USF model" swab 227 compared to the Roche cobas sampling kit (97.03% agreement, Kappa 0.863) (10). In a study 228 comparing swabs from four distinct 3D-printing manufacturers to the Copan swab (501CS01) 229 using a RT-PCR run on a Abbott m2000 RealTime system platform, high degree of concordance 230

with Kappa values between [0.85-0.89] were observed (16). An additional prospective clinical 231 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 30, 2021. To our knowledge, this is the first study reporting on autonomous hospital-based production and 237 evaluation of 3D printed swabs. The implementation of our hospital-based platform was facilitated 238 by the existing "Health-related 3D printing centre" in our institution, which normally serves the 239 needs of the Radiation Oncology department and other hospital sectors, but quickly reoriented its 240 efforts to provide healthcare workers with the much-needed protection equipment and diagnostic 241 tools. Additionally, we had access to an institutional sterilization service that allowed us to easily 242 perform the steam sterilization that was chosen as a rapid, nontoxic and inexpensive technique that 243 is microbicidal and sporicidal, and was previously shown to be compatible with the Surgical Guide 244 resin (18). Actual installations and staff availability allowed us to limit the production costs of 3D 245 printed swabs. The total cost per swab was about 0.56USD, which included 0.26USD for 246 consumables and 0.29USD for staff wages. Further optimization has yet to be realized to increase 247 the production volume and lower the production costs. 248

In conclusion, our study adds to the few clinical validation studies that demonstrated safety and 250 accuracy of 3D swabs. Our study is unique in that it tested a fully integrated hospital-based 251 production of 3D-printed swabs as initially suggested by the USF and Northwell Health system 252 groups. Our clinical trial has demonstrated that our local 3D printed swab production line offers a 253 reliable local alternative to commercial swabs and therefore confirms that it is a viable local 254 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 30, 2021. Statistical analyses are detailed in Table 1 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 30, 2021. ; https://doi.org/10.1101/2021.05.26.21257548 doi: medRxiv preprint

Patients with Pneumonia in China

The Novel

2019-nCoV, is Highly Contagious and More Infectious Than Initially 281 Estimated

SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat

WHO Director-General's opening remarks at the 285 media briefing on COVID-19 -11

Diagnostic Testing for Severe Acute Respiratory Syndrome-Related 290

Coronavirus 2: A Narrative Review

Nasopharyngeal Swabs Are More Sensitive Than Oropharyngeal 293 Swabs for COVID-19 Diagnosis and Monitoring the SARS-CoV-2 Load

The global rise of 3D printing during the COVID-19 pandemic

Open Development 327 and Clinical Validation of Multiple 3D-Printed Nasopharyngeal Collection Swabs: Rapid 328 Resolution of a Critical COVID-19 Testing Bottleneck

Prospective clinical validation of 3D printed 330 nasopharyngeal swabs for diagnosis of COVID-19

Effects of Steam Sterilization on 3D Printed Biocompatible Resin Materials for Surgical 333

Guides-An Accuracy Assessment Study

Resurgence of COVID-19 in

New SARS-CoV-2 Variants -Clinical, Public

Health, and Vaccine Implications